Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: verheijen rh. J Clin Oncol. 2005 Oct 1;23(28):6890-8. doi: 10.1200/JCO.2005.02.626. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129845 Free article.
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: verheijen rh. J Clin Oncol. 2006 Aug 1;24(22):3576-82. doi: 10.1200/JCO.2005.05.1896. J Clin Oncol. 2006. PMID: 16877724 Free article.
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA. Hermsen BB, et al. Among authors: verheijen rh. Br J Cancer. 2007 May 7;96(9):1335-42. doi: 10.1038/sj.bjc.6603725. Epub 2007 Apr 10. Br J Cancer. 2007. PMID: 17426707 Free PMC article.
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer.
Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, Van der Velden J, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Van der Zee AG, et al. Among authors: verheijen rh. J Clin Oncol. 2008 Feb 20;26(6):884-9. doi: 10.1200/JCO.2007.14.0566. J Clin Oncol. 2008. PMID: 18281661 Free article. Clinical Trial.
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J, Seiden MV. Verheijen RH, et al. J Clin Oncol. 2006 Feb 1;24(4):571-8. doi: 10.1200/JCO.2005.02.5973. J Clin Oncol. 2006. PMID: 16446329 Free article. Clinical Trial.
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study.
Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, van Dorst EB, van der Velden J, Hermans RH, van der Putten HW, Drouin P, Runnebaum IB, Sluiter WJ, van der Zee AG. Oonk MH, et al. Among authors: verheijen rh. Lancet Oncol. 2010 Jul;11(7):646-52. doi: 10.1016/S1470-2045(10)70104-2. Epub 2010 May 25. Lancet Oncol. 2010. PMID: 20537946
266 results